To appraise the clinical and cost effectiveness of letermovir within its marketing authorisation for preventing cytomegalovirus infection in sero-positive patients having allogeneic haematopoietic stem cell transplantation.
Status Proposed
Process STA
ID number 1153

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
14 July 2017 - 11 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance